Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

We systematically reviewed the current knowledge on fixed-dose triple therapies for the
treatment of chronic obstructive pulmonary disease (COPD), with a specific focus on its …

Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …

Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive
pulmonary disease (COPD). However, there are limited data available on the response to …

Background: This study compared real-world patient-reported outcomes (PROs) measured
by the Clinical COPD Questionnaire (CCQ), the London Chest Activities of Daily Living …

In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …

Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …

Background Although exacerbation and mortality are the most important clinical outcomes of
stable chronic obstructive pulmonary disease (COPD), the drug classes that are the most …

Background: Triple therapy (long-acting muscarinic antagonist [LAMA] plus long-acting
beta2-agonist [LABA] plus inhaled corticosteroid [ICS]) is recommended by the Global …

Background: Randomized clinical trials have shown long-acting mono bronchodilator
therapy to be efficacious in improving lung function and dyspnea, while reducing …